Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
- Conditions
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- East Florida Eye Institute
- Target Recruit Count
- 80
- Registration Number
- NCT02296567
- Locations
- 🇺🇸
East Florida Eye Institute, Stuart, Florida, United States
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Associated Retinal Consultants, Michigan
- Target Recruit Count
- 13
- Registration Number
- NCT02291887
- Locations
- 🇺🇸
Associated Retinal Consultants, Royal Oak, Michigan, United States
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
- Conditions
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Anders Kvanta
- Target Recruit Count
- 40
- Registration Number
- NCT02274259
- Locations
- 🇸🇪
St Eriks Eye Hospital, Stockholm, Sweden
Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02258009
- Locations
- 🇩🇪
Novartis Investigative Site, Chemnitz, Germany
Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 20
- Registration Number
- NCT02257502
- Locations
- 🇫🇷
Hospices Civils de Lyon - Hôpital de la Croix-Rousse, Lyon, France
Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
- Conditions
- Interventions
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 30
- Registration Number
- NCT02218177
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 5
- Registration Number
- NCT02204683
- Locations
- 🇺🇸
University of Nebraska Medical Center, Truhlsen Eye Institute, Omaha, Nebraska, United States
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT02192541
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.
- Conditions
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 59
- Registration Number
- NCT02174211
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, UK, United Kingdom
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Centre Hospitalier Intercommunal Creteil
- Target Recruit Count
- 90
- Registration Number
- NCT02157077
- Locations
- 🇫🇷
Cabinet Alpes Rétine, Montbonnot-Saint-Martin, France
🇫🇷CHR Hôtel Dieu, Nantes, France
🇫🇷Hôpital Pellegrin, Bordeaux, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.